Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

On the Road to Leucine-Rich Repeat Kinase 2 Signalling: Evidence from Cellular and in vivo Studies
Veronique Daniëls, Veerle Baekelandt, Jean‐Marc Taymans
Neurosignals (2011) Vol. 19, Iss. 1, pp. 1-15
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences
Nicole Exner, A. Kathrin Lutz, Christian Haass, et al.
The EMBO Journal (2012) Vol. 31, Iss. 14, pp. 3038-3062
Open Access | Times Cited: 568
Perspective on the current state of the LRRK2 field
Jean‐Marc Taymans, Matt Fell, Tim Greenamyre, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 66
Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity
Frank Gillardon, Ralph A. Schmid, Henning J. Draheim
Neuroscience (2012) Vol. 208, pp. 41-48
Closed Access | Times Cited: 204
LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors
Kelly M. Hinkle, Mei Yue, Bahareh Behrouz, et al.
Molecular Neurodegeneration (2012) Vol. 7, Iss. 1
Open Access | Times Cited: 183
GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor
Alastair D. Reith, Paul Bamborough, Karamjit S. Jandu, et al.
Bioorganic & Medicinal Chemistry Letters (2012) Vol. 22, Iss. 17, pp. 5625-5629
Open Access | Times Cited: 143
Brain Penetrant LRRK2 Inhibitor
Hwan Geun Choi, Jinwei Zhang, Xianming Deng, et al.
ACS Medicinal Chemistry Letters (2012) Vol. 3, Iss. 8, pp. 658-662
Open Access | Times Cited: 124
LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
Jean‐Marc Taymans, Renée Vancraenenbroeck, Petri Ollikainen, et al.
PLoS ONE (2011) Vol. 6, Iss. 8, pp. e23207-e23207
Open Access | Times Cited: 101
Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies
Paul Davies, Kelly M. Hinkle, Nour N. Sukar, et al.
Biochemical Journal (2013) Vol. 453, Iss. 1, pp. 101-113
Open Access | Times Cited: 93
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson’s disease mutations and LRRK2 pharmacological inhibition
Elizabeth A. Doggett, Jing Zhao, Christina N. Mork, et al.
Journal of Neurochemistry (2011) Vol. 120, Iss. 1, pp. 37-45
Closed Access | Times Cited: 88
Montelukast-Induced Adverse Drug Reactions: A Review of Case Reports in the Literature
Gioacchino Calapai, Marco Casciaro, Marco Miroddi, et al.
Pharmacology (2014) Vol. 94, Iss. 1-2, pp. 60-70
Open Access | Times Cited: 86
Characterization of TAE684 as a potent LRRK2 kinase inhibitor
Jinwei Zhang, Xianming Deng, Hwan Geun Choi, et al.
Bioorganic & Medicinal Chemistry Letters (2012) Vol. 22, Iss. 5, pp. 1864-1869
Open Access | Times Cited: 85
LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?
Jean‐Marc Taymans, Elisa Greggio
Current Neuropharmacology (2016) Vol. 14, Iss. 3, pp. 214-225
Open Access | Times Cited: 73
(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse
Jun-Shiao Chou, Chuyu Chen, Ying‐Ling Chen, et al.
Neurobiology of Disease (2014) Vol. 68, pp. 190-199
Closed Access | Times Cited: 64
The GTPase function of LRRK2
Jean‐Marc Taymans
Biochemical Society Transactions (2012) Vol. 40, Iss. 5, pp. 1063-1069
Closed Access | Times Cited: 52
Differential protein–protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways
Lauran Reyniers, Maria Grazia Del Giudice, Laura Civiero, et al.
Journal of Neurochemistry (2014) Vol. 131, Iss. 2, pp. 239-250
Open Access | Times Cited: 51
Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor
John M. Hatcher, Jinwei Zhang, Hwan Geun Choi, et al.
ACS Medicinal Chemistry Letters (2015) Vol. 6, Iss. 5, pp. 584-589
Open Access | Times Cited: 49
Phosphorylation of LRRK2: from kinase to substrate
Evy Lobbestael, Veerle Baekelandt, Jean‐Marc Taymans
Biochemical Society Transactions (2012) Vol. 40, Iss. 5, pp. 1102-1110
Closed Access | Times Cited: 45
The Parkinson's Disease-Associated LRRK2 Mutation R1441G Inhibits Neuronal Differentiation of Neural Stem Cells
Lamia'a Bahnassawy, Sarah Nicklas, Thomas Palm, et al.
Stem Cells and Development (2013) Vol. 22, Iss. 18, pp. 2487-2496
Closed Access | Times Cited: 43
Small-Molecule Inhibitors of LRRK2
John M. Hatcher, Hwan Geun Choi, Dario R. Alessi, et al.
Advances in neurobiology (2017), pp. 241-264
Closed Access | Times Cited: 39
Development of a highly potent and selective degrader of LRRK2
John M. Hatcher, Monika Zwirek, Adil R. Sarhan, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 94, pp. 129449-129449
Closed Access | Times Cited: 10
Highly Dynamic Exon Shuffling in Candidate Pathogen Receptors ... What if Brown Algae Were Capable of Adaptive Immunity?
Antonios Zambounis, Marek Eliáš, Lieven Sterck, et al.
Molecular Biology and Evolution (2011) Vol. 29, Iss. 4, pp. 1263-1276
Open Access | Times Cited: 34
Prediction of the Repeat Domain Structures and Impact of Parkinsonism-Associated Variations on Structure and Function of all Functional Domains of Leucine-Rich Repeat Kinase 2 (LRRK2)
Ryan D. Mills, Terrence D. Mulhern, Fei Liu, et al.
Human Mutation (2014) Vol. 35, Iss. 4, pp. 395-412
Open Access | Times Cited: 33
Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
Renée Vancraenenbroeck, Evy Lobbestael, Marc De Maeyer, et al.
CNS & Neurological Disorders - Drug Targets (2011) Vol. 10, Iss. 6, pp. 724-740
Closed Access | Times Cited: 30
Drug discovery in Parkinson's disease: update and developments in the use of cellular models
Steven Finkbeiner, Skibinski
International Journal of High Throughput Screening (2011), pp. 15-15
Open Access | Times Cited: 29
Reappraisal to the study of 4E-BP1 as an mTOR substrate – A normative critique
Asiya Batool, Sabreena Aashaq, Khurshid Iqbal Andrabi
European Journal of Cell Biology (2017) Vol. 96, Iss. 4, pp. 325-336
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top